243 related articles for article (PubMed ID: 15867366)
21. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
22. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
23. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
24. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
Lipton A; Campbell-Baird C; Harvey H; Kim C; Demers L; Costa L
Am J Clin Oncol; 2010 Feb; 33(1):75-8. PubMed ID: 19652577
[TBL] [Abstract][Full Text] [Related]
26. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
27. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
29. Maspin reduces prostate cancer metastasis to bone.
Hall DC; Johnson-Pais TL; Grubbs B; Bernal R; Leach RJ; Padalecki SS
Urol Oncol; 2008; 26(6):652-8. PubMed ID: 18367129
[TBL] [Abstract][Full Text] [Related]
30. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
31. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
33. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
34. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
35. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.
Muguruma H; Yano S; Kakiuchi S; Uehara H; Kawatani M; Osada H; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8822-8. PubMed ID: 16361571
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
37. Antivascular therapy of cancer metastasis.
Fidler IJ
J Surg Oncol; 2006 Sep; 94(3):178-80. PubMed ID: 16900530
[No Abstract] [Full Text] [Related]
38. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
